Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.6
Journals
Current Oncology
Special Issues
New Treatments in Pancreatic Ductal Adenocarcinoma
share announcement

New Treatments in Pancreatic Ductal Adenocarcinoma

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 31 October 2024 | Viewed by 1289

Special Issue Editor

Dr. Kelly J. Lafaro

E-Mail Website
Guest Editor
Department of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Interests: gastrointestinal surgical oncology; hepatobiliary surgery

Special Issue Information

Dear Colleagues,

Pancreatic ductal adenocarcinoma (PDAC) continues to increase in incidence; however, survival remains dismal. A large percentage of patients are diagnosed at a late stage when surgery is not technically feasible, leaving few treatment options. A lack of reliable methods of early detection and its therapeutic resistance makes it one of the most highly lethal malignancies. New treatment strategies are being investigated which may ultimately improve the prognosis of pancreatic cancer and potentially convert later-stage patients to having a resectable disease. New treatments for pancreatic cancer are aided by improvements in radiologic imaging, analysis and manipulation of the tumor microenvironment, genomic diagnostics, understanding of pancreatic tumor biology and advances in surgical techniques.

In this Special Issue of Current Oncology, we invite authors to submit work focusing on new treatments in PDAC. Original articles, as well as review articles focusing on advances in radiologic, medical, surgical, and radiation therapy for pancreatic cancer are welcome.

I look forward to hearing from you.

Dr. Kelly J. Lafaro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • novel treatments
  • novel therapies
  • targeted therapies
  • immune therapy
  • vaccine therapy
  • pancreatic ductal adenocarcinoma
  • pancreatic surgery
  • chemotherapy for pancreatic cancer
  • surgery

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 1685 KiB  
Review
Multimodal Approaches to Patient Selection for Pancreas Cancer Surgery
by Hala Muaddi, LaDonna Kearse and Susanne Warner
Curr. Oncol. 2024, 31(4), 2260-2273; https://doi.org/10.3390/curroncol31040167 - 15 Apr 2024
Viewed by 751
Abstract
With an overall 5-year survival rate of 12%, pancreas ductal adenocarcinoma (PDAC) is an aggressive cancer that claims more than 50,000 patient lives each year in the United States alone. Even those few patients who undergo curative-intent resection with favorable pathology reports are [...] Read more.
With an overall 5-year survival rate of 12%, pancreas ductal adenocarcinoma (PDAC) is an aggressive cancer that claims more than 50,000 patient lives each year in the United States alone. Even those few patients who undergo curative-intent resection with favorable pathology reports are likely to experience recurrence within the first two years after surgery and ultimately die from their cancer. We hypothesize that risk factors for these early recurrences can be identified with thorough preoperative staging, thus enabling proper patient selection for surgical resection and avoiding unnecessary harm. Herein, we review evidence supporting multidisciplinary and multimodality staging, comprehensive neoadjuvant treatment strategies, and optimal patient selection for curative-intent surgical resections. We further review data generated from our standardized approach at the Mayo Clinic and extrapolate to inform potential future investigations. Full article
(This article belongs to the Special Issue New Treatments in Pancreatic Ductal Adenocarcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop